Method Peptides · Research compound
$15 flat rate on orders under $200.
Tracking is provided when the order ships.
Research reference
Product specifications, research context, and handling information.
CJC-1295 No DAC, also known as Modified GRF (1-29), is a synthetic growth hormone-releasing hormone analog studied for its relationship to pulsatile growth hormone signaling, pituitary receptor activity, and endocrine pathway research.
In research settings, CJC-1295 No DAC is commonly evaluated for its interaction with GHRH receptor pathways, pituitary signaling models, growth hormone pulse dynamics, IGF-1-related signaling, and endocrine regulation research.
CJC-1295 No DAC is a modified GHRH (1-29) analog studied for its ability to interact with growth hormone-releasing hormone receptors. Research models evaluate how this interaction may influence pituitary signaling, growth hormone pulse activity, and downstream endocrine pathway communication.
Because it does not include DAC, CJC-1295 No DAC is often studied in models focused on shorter-duration, pulse-based signaling rather than extended-duration receptor activity.
CJC-1295 No DAC has gained interest in endocrine and growth hormone research due to its relationship with GHRH receptor activity, pituitary signaling, growth hormone pulse dynamics, and IGF-1-associated pathway analysis.
It is also commonly discussed in research contexts involving hypothalamic-pituitary axis models, metabolic signaling, hormone-regulated cellular activity, and pulse-based endocrine research.
This product is intended strictly for laboratory and research purposes. Not for human consumption, medical use, diagnostic use, or therapeutic use.
